City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Jana Portnow, MD  
Search results:  8  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-8 Trials Jump to page:

COH Protocol Number: 16169

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for SS- Treatment Use of Neratinib for EGFR-positive High-grade Glioma

COH Protocol Number: 16114

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for PC for Treatment of Rindopepimut (CDX-110)

COH Protocol Number: 16062 ClinicalTrials.gov Number: NCT02546102

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase III Randomized Double-blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

COH Protocol Number: 15448

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for SA for Treatment with Rindopepimut (CDX-110) and Bevacizumab

COH Protocol Number: 15331 ClinicalTrials.gov Number: NCT02308020

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma

COH Protocol Number: 14312 ClinicalTrials.gov Number: NCT02338037

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients with Brain Tumors

COH Protocol Number: 14108 ClinicalTrials.gov Number: NCT02192359

Principal Investigator: Jana Portnow, MD
Sponsor: NCI Approved External Peer Review

Title:  A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas

COH Protocol Number: 13401 ClinicalTrials.gov Number: NCT02015819

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination with Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas

 
Results per page: 25 50 100 All 1-8 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.